EA202190445A2 - Раствор для перорального введения - Google Patents

Раствор для перорального введения

Info

Publication number
EA202190445A2
EA202190445A2 EA202190445A EA202190445A EA202190445A2 EA 202190445 A2 EA202190445 A2 EA 202190445A2 EA 202190445 A EA202190445 A EA 202190445A EA 202190445 A EA202190445 A EA 202190445A EA 202190445 A2 EA202190445 A2 EA 202190445A2
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
oral solution
salt
compound
oral
Prior art date
Application number
EA202190445A
Other languages
English (en)
Russian (ru)
Inventor
Аяко Окамото
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA202190445A2 publication Critical patent/EA202190445A2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA202190445A 2011-10-19 2012-10-19 Раствор для перорального введения EA202190445A2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19

Publications (1)

Publication Number Publication Date
EA202190445A2 true EA202190445A2 (ru) 2021-08-31

Family

ID=47178263

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201490812A EA201490812A1 (ru) 2011-10-19 2012-10-19 Раствор для перорального введения
EA202190445A EA202190445A2 (ru) 2011-10-19 2012-10-19 Раствор для перорального введения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201490812A EA201490812A1 (ru) 2011-10-19 2012-10-19 Раствор для перорального введения

Country Status (35)

Country Link
US (8) US20140303183A1 (enExample)
EP (1) EP2768508B1 (enExample)
JP (1) JP6077534B2 (enExample)
KR (1) KR101856283B1 (enExample)
CN (2) CN107823131A (enExample)
AR (1) AR088372A1 (enExample)
AU (2) AU2012326978B2 (enExample)
BR (1) BR112014009330A2 (enExample)
CA (1) CA2851999C (enExample)
CL (1) CL2014000967A1 (enExample)
CO (1) CO6950486A2 (enExample)
CY (1) CY1117794T1 (enExample)
DK (1) DK2768508T3 (enExample)
EA (2) EA201490812A1 (enExample)
ES (1) ES2583137T3 (enExample)
HR (1) HRP20160989T1 (enExample)
HU (1) HUE028869T2 (enExample)
IL (1) IL231988A (enExample)
IN (1) IN2014DN02987A (enExample)
JO (1) JO3190B1 (enExample)
LT (1) LT2768508T (enExample)
ME (1) ME02459B (enExample)
MX (1) MX347309B (enExample)
MY (1) MY169096A (enExample)
PH (1) PH12014500816A1 (enExample)
PL (1) PL2768508T3 (enExample)
PT (1) PT2768508T (enExample)
RS (1) RS54967B1 (enExample)
SG (1) SG11201401273SA (enExample)
SI (1) SI2768508T1 (enExample)
SM (1) SMT201600341B (enExample)
TW (2) TWI679977B (enExample)
UA (1) UA111506C2 (enExample)
WO (1) WO2013058411A1 (enExample)
ZA (1) ZA201402669B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
UA124498C2 (uk) * 2015-12-01 2021-09-29 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти)
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
EP3582765B1 (en) * 2017-10-10 2021-04-28 Vertice Pharma, LLC Midodrine hydrochloride oral solution and uses thereof
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
JP2021115288A (ja) * 2020-01-28 2021-08-10 青葉化成株式会社 液状組成物および液状医療材料
US12109195B2 (en) 2020-06-30 2024-10-08 Vireo Systems, Inc. Compositions and methods for treatment of vaginal infections
EP4171513A4 (en) * 2020-06-30 2024-07-17 VIREO Systems, Inc. COMPOSITIONS FOR ODOUR AND ITCHING CONTROL AND METHODS AND DEVICES FOR THEIR ADMINISTRATION
TWI820673B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑口溶膜組合物、其製備方法及用途
CN115414322A (zh) * 2022-07-05 2022-12-02 杭州民生药物研究院有限公司 一种富马酸卢帕他定口服液体制剂及其制备工艺
CN116966140A (zh) * 2023-08-18 2023-10-31 四川阿赛斯生物科技有限公司 一种含有布瑞哌唑的口服溶液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
KR101027570B1 (ko) * 2002-05-03 2011-04-06 이스라엘 인스티튜트 포 바이올로지컬 리서치 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
KR101328857B1 (ko) * 2005-06-13 2013-11-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 가용화 제제
ATE514416T1 (de) * 2005-09-01 2011-07-15 Baxter Internat Inc A Delaware Corp Argatrobanformulierung mit einer säure als lösungsvermittler
US20100004267A1 (en) * 2006-07-31 2010-01-07 Asubio Pharma Co., Ltd. Liquid preparation
JP2010539173A (ja) * 2007-09-17 2010-12-16 シェーリング コーポレイション サイクリン依存キナーゼ阻害化合物を含む製剤およびこの製剤を用いて腫瘍を処置する方法
US20090082326A1 (en) * 2007-09-21 2009-03-26 Forest Laboratories Holdings Limited Soluble dosage forms containing cephem derivatives suitable for parenteral administration
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
NZ603076A (en) * 2010-08-24 2014-12-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Also Published As

Publication number Publication date
US20170182036A1 (en) 2017-06-29
US20210236483A1 (en) 2021-08-05
TWI632921B (zh) 2018-08-21
AU2012326978B2 (en) 2017-08-31
MY169096A (en) 2019-02-18
CL2014000967A1 (es) 2014-10-03
EA201490812A1 (ru) 2014-09-30
EP2768508B1 (en) 2016-07-06
US20180271858A1 (en) 2018-09-27
HUE028869T2 (en) 2017-01-30
PL2768508T3 (pl) 2016-12-30
EP2768508A1 (en) 2014-08-27
TW201737916A (zh) 2017-11-01
TWI679977B (zh) 2019-12-21
KR101856283B1 (ko) 2018-05-09
TW201330873A (zh) 2013-08-01
CY1117794T1 (el) 2017-05-17
BR112014009330A2 (pt) 2017-04-11
NZ623523A (en) 2015-12-24
ZA201402669B (en) 2015-09-30
CO6950486A2 (es) 2014-05-20
JO3190B1 (ar) 2018-03-08
DK2768508T3 (en) 2016-08-29
JP2014530801A (ja) 2014-11-20
SG11201401273SA (en) 2014-05-29
LT2768508T (lt) 2016-09-12
PH12014500816A1 (en) 2014-05-19
SI2768508T1 (sl) 2016-09-30
RS54967B1 (sr) 2016-11-30
US20200171023A1 (en) 2020-06-04
CA2851999A1 (en) 2013-04-25
CN103889426A (zh) 2014-06-25
ES2583137T3 (es) 2016-09-19
AR088372A1 (es) 2014-05-28
AU2017213570A1 (en) 2017-08-31
US20240009186A1 (en) 2024-01-11
CA2851999C (en) 2020-01-07
WO2013058411A1 (en) 2013-04-25
MX347309B (es) 2017-04-21
HRP20160989T1 (hr) 2016-10-07
AU2012326978A1 (en) 2014-05-22
CN107823131A (zh) 2018-03-23
JP6077534B2 (ja) 2017-02-08
MX2014004529A (es) 2014-08-01
KR20140083032A (ko) 2014-07-03
UA111506C2 (uk) 2016-05-10
IL231988A0 (en) 2014-05-28
SMT201600341B (it) 2016-11-10
US20250099460A1 (en) 2025-03-27
IN2014DN02987A (enExample) 2015-05-08
ME02459B (me) 2017-02-20
IL231988A (en) 2017-09-28
US20140303183A1 (en) 2014-10-09
US20160213665A1 (en) 2016-07-28
HK1196773A1 (zh) 2014-12-24
PT2768508T (pt) 2016-08-17

Similar Documents

Publication Publication Date Title
EA202190445A2 (ru) Раствор для перорального введения
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
PH12012502568A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
MX2016004992A (es) Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
MX355228B (es) Composicion fungicida agricola y horticola.
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
UA111770C2 (uk) Інгібітори бромдомену
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
EA201390347A1 (ru) Лечение заболеваний
UA105229C2 (uk) Фармацевтичний склад
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201290416A1 (ru) Новые спиропиперидиновые соединения
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
UA112556C2 (uk) Інсектицидні похідні 2-метоксибензамідів
MX2014002210A (es) Derivado de acido pirrolidin-3-ilacetico.
TH148781A (th) สารละลายสำหรับการให้ทางช่องปาก
TH97363B (th) สารละลายสำหรับการให้ทางช่องปาก
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
MA33882B1 (fr) Nouveaux derives azabicyclo [3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
HK1184972A1 (zh) 化合物及用於抑制磷酸盐转运的方法
UA107092C2 (uk) Заміщені похідні карбамоїлметиламінооцтової кислоти як інгібітори nep